Pricing Log in Create free account
Saturday 17 October 2026 Export CRON’s income statement to Excel — free account

Cronos Group Inc.

CRON Healthcare Drug Manufacturers Specialty & Generic

Cronos Group Inc.’s revenue for fiscal 2025 (year ended December 2025) was $146.6 million, up 24.6% from fiscal 2024. In the quarter to June 2026, revenue grew 58.4%, EPS grew 190.0%, free cash flow grew 2,279.2% and total debt fell 4.71%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.

3.22 0.02 +0.63%
Market cap
$1.2B
P/E
16.1×
Fwd P/E
32.2×
Dividend yield
—
F-score
5/9
Altman Z
12.67
Beneish M
−2.05
Dividend safety
20/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 51.20%

Capital & Financial Ratios $m

Market Cap 1,180.00
Revenue 179.09
Net Income 79.20
Free Cash Flow 49.44
Net Debt (795.89)
Current Ratio 16.18 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 16.10
Fwd P/E 32.20
P/S ratio 6.72
P/B ratio 1.08
Past 5Y EPS Growth —
This Y EPS Growth 860.00% (at or above 15%: strong)
Next Y EPS Growth 3.62%
Next Y revenue growth 25.94% (at or above 10%: strong)
Next 5Y EPS Growth 2.94%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.3×, against a ten-year median of 2.9×; over the ten years it ranged from −2.1× in 2023 to 392× in 2018.
P/E against its own 10 years 49.69%
10-year low 10-year high
P/S against its own 10 years 13.03%
10-year low 10-year high
P/B against its own 10 years 55.11%
10-year low 10-year high
EV/Sales against its own 10 years 30.82%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2018 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 862 859 832 797
Receivables 30 29 57 57
Inventory 30 33 47 53
Other — — — —
933 936 944 912
2023 2024 2025 Q'26
Payables 12 17 12 17
ST’ Debt — — — —
Other 0 0 — —
41 50 48 56

Compound Annual Growth %

10y 5y 3y
Sales — 25.70% 19.11%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — (7.72%) 0.06%

Revenue $m

Mar Jun Sep Dec Year
’26 45 53 — — —
’25 32 33 36 45 147
’24 25 28 34 30 118
’23 19 19 25 24 87
’22 25 22 20 20 87
’21 13 16 20 26 74
’20 8 10 11 17 47
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 11 24 — — —
’25 (2) 3 13 12 26
’24 (2) 2 12 8 19
’23 (48) (12) 0 17 (43)
’22 (34) (17) (13) (24) (89)
’21 (47) (40) (31) (36) (154)
’20 (39) (39) (28) (38) (145)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 9 22 — — —
’25 (17) (1) 9 10 0
’24 (4) 1 5 4 6
’23 (48) (12) (1) 15 (46)
’22 (35) (19) (15) (25) (94)
’21 (54) (42) (34) (37) (166)
’20 (46) (48) (36) (49) (180)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 0.04 0.09 — — —
’25 0.02 (0.10) 0.07 0.00 (0.02)
’24 (0.01) (0.02) 0.02 0.11 0.11
’23 (0.05) (0.02) 0.00 (0.12) (0.19)
’22 (0.09) (0.05) (0.10) (0.21) (0.45)
’21 (0.44) 0.15 0.21 (0.36) (1.07)
’20 0.20 (0.31) 0.19 (0.31) (0.21)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.4
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — 5.12 6.04 4.00 3.79 2.45 1.64 1.86 1.60

Analyst estimates 2026–2028

Powerpack
High — — 15.30 25.10 9.15 15.83 4.31 2.64 3.14 3.43
People
People Employees 74 148 291 631 665 626 447 356 459 610
Revenue/emp, $m 0.01 0.02 0.04 0.04 0.07 0.12 0.19 0.25 0.26 0.24
Income, $m
Income, $m Revenue 0 3 12 24 47 74 87 87 118 147
Gross margin, % 359.64 177.12 51.26 (74.09) (55.29) (23.56) 17.79 13.65 21.42 42.81
EBT (1) 2 (22) 1,166 (73) (397) (121) (74) 37 (17)
EBT margin, % (317.25) 68.32 (179.99) 4,909.21 (156.84) (533.53) (139.49) (84.44) 31.11 (11.68)
Net income (1) 2 (22) 1,166 (75) (397) (169) (75) 40 (3)
Depreciation 0 1 2 4 11 15 13 8 9 14
Per share, $
Per share, $ Revenue 0.01 0.02 0.07 0.08 0.13 0.20 0.23 0.23 0.31 0.38
Earnings (0.01) 0.01 (0.13) 3.76 (0.21) (1.07) (0.45) (0.19) 0.11 (0.02)
Cash flow (0.06) (0.03) (0.04) (0.42) (0.41) (0.41) (0.24) (0.11) 0.05 0.07
Capex (0.01) (0.24) (0.51) (0.13) (0.10) (0.03) (0.01) (0.01) (0.03) (0.07)
Free cash flow (0.08) (0.28) (0.56) (0.55) (0.51) (0.45) (0.25) (0.12) 0.01 0.00
Book value 0.33 0.49 0.86 5.64 4.86 3.60 3.03 2.88 2.91 2.98
Shares, m 78 135 172 310 352 370 377 381 382 383
Valuation, ×
Valuation, × P/E 769.70 769.70 0.00 1.93 0.00 0.00 0.00 0.00 19.52 0.00
P/S 326.22 326.22 147.67 100.14 52.23 19.51 10.86 9.21 6.56 6.88
P/B 15.42 15.42 12.05 1.36 1.43 1.09 0.83 0.73 0.69 0.88
EV/Sales 325.50 325.50 145.70 37.01 24.80 6.10 0.78 (0.64) (0.73) 1.21
EV/FCF (27.54) (27.54) (18.38) (5.19) (6.43) (2.74) (0.72) 1.20 (15.12) (936.49)
Cash, $m
Cash, $m Operating cash flow (5) (4) (8) (130) (145) (154) (89) (43) 19 26
Capex (1) (33) (89) (39) (35) (12) (5) (3) (13) (26)
Free cash flow (6) (37) (96) (169) (180) (166) (94) (46) 6 0
Balance, $m
Balance, $m Working capital 0 15 7 1,240 1,165 1,025 892 892 886 896
Total debt 3 4 0 7 8 7 3 2 1 1
Net debt 0 (3) (24) (1,499) (1,281) (998) (875) (860) (858) (831)
Shareholders’ equity 25 67 149 1,749 1,708 1,334 1,141 1,096 1,111 1,143
Returns, %
Returns, % ROA (1.52) 3.48 (16.55) 102.60 (3.64) (23.84) (12.93) (6.29) 3.56 (0.80)
ROIC (3.89) (1.60) (10.70) (30.32) (26.26) (36.55) (25.38) (22.44) (18.89) (3.34)
ROE (1.91) 4.17 (20.11) 122.95 (4.23) (26.04) (13.63) (6.61) 3.72 (0.84)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Cronos Group Inc. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
XERS Xeris Biopharma Holdings, Inc. $1.8B — (loss-making) 54.5× +28.74% (above 0%: growing) n/m +8,403.09% (above 0%: growing) 86.41% 5.62% Compare
ANIP ANI Pharmaceuticals, Inc. $1.7B 14.9× 14.5× +25.87% (above 0%: growing) +194.59% (above 0%: growing) −22.19% (below 0%: shrinking) 62.35% 15.21% Compare
PAHC Phibro Animal Health Corporation $1.5B 15.8× 11.1× +4.77% (above 0%: growing) +28.57% (above 0%: growing) −35.73% (below 0%: shrinking) 33.88% 12.14% Compare
ETON Eton Pharmaceuticals, Inc. $1.5B 107× 40.3× +98.59% (above 0%: growing) n/m −8.78% (below 0%: shrinking) 67.61% 34.04% Compare
PCRX Pacira BioSciences, Inc. $1.5B 104× 33.7× +6.24% (above 0%: growing) n/m +502.51% (above 0%: growing) 77.05% 2.22% Compare
CRON Cronos Group Inc. $1.2B 16.1× 32.2× +58.44% (above 0%: growing) n/m +2,279.22% (above 0%: growing) 53.67% 13.97%
AMPH Amphastar Pharmaceuticals, Inc. $1.1B 14.9× 14.7× +5.44% (above 0%: growing) +4.55% (above 0%: growing) +87.61% (above 0%: growing) 50.83% 21.60% Compare
HROW Harrow, Inc. $1.1B — (loss-making) 134× +10.85% (above 0%: growing) n/m −838.78% (below 0%: shrinking) 71.27% (15.58%) Compare
COLL Collegium Pharmaceutical, Inc. $754.6M 15.2× 12.5× +6.32% (above 0%: growing) n/m −2.14% (below 0%: shrinking) 55.18% 1.85% Compare
Median of peers $1.5B 15.5× 24.2× +8.59% +28.57% −5.46% 64.98% 8.88%

All 86 Drug Manufacturers Specialty & Generic stocks →

Cronos Group Inc. (CRON) key facts

  • Strength: Cronos Group Inc.’s revenue for fiscal 2025 (year ended December 2025) was $146.6 million, up 24.6% from fiscal 2024.
  • Cronos Group Inc. (CRON) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, CRON traded at $3.22, a market capitalization of $1.2 billion.
  • Return on equity was −0.84% and debt-to-equity 0.00.
  • Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 12.67 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Cronos Group Inc. (CRON) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/CRON · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com